Amryt

EMA has 67 days to decide whether to back recommendation of its expert committee

Dublin-based biopharma group says most of the funds to be used to repay existing loan

Rare disease specialist says performance was ‘strong’ in ‘extremely busy’ period

Company upgrades forecasts as it completes Chiasma takeover

Drug group expands its portfolio of medicines while reporting first-quarter numbers

Company developing drug for rare butterfly skin condition

Group plots dual Nasdaq listing to create enlarged rare disease company

Lojuxta revenues driven by UK, France reimbursement approval

Biopharma firm signs new deal for gene therapy that could treat genetic condition EB